Assessing and Modulating Immune Recovery After Transplant
Official title: Using the Composite Immune Risk Score to Assess and Modulate the Patient's Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation, a Prospective, Multicenter, Randomized Controlled Study.
Run by Institute of Hematology & Blood Diseases Hospital, China · NCT06208137 · Data updated 2026-11-12
This study is testing whether a new way to track and support patients after a specific type of stem cell transplant can help them recover their immune system better.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 16 Years and up |
| Sex | All |
| Enrollment | 456 (estimated) |
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China Academic / other |
| Locations | 1 site (Tianjin, Tianjin Municipality) |
| Status | Recruiting |
| Started | February 29, 2024 |
| Main results expected | October 1, 2027 |
| Study ends | April 1, 2028 |
| Registry record updated | August 13, 2024 |
| Trial ID | NCT06208137 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients aged 16 and older who are receiving haploidentical allo-HSCT.
✕Probably not a fit
Patients undergoing tandem or multiple transplantations or those with conditions that prevent compliance may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of the Composite Immune Risk Score in managing patients who have undergone haploidentical allo-HSCT. It focuses on health monitoring and providing regular follow-up reminders to improve patient outcomes. The goal is to assess how these interventions can enhance immune reconstitution in a real-world clinical setting. By tracking patients' immune responses, the study aims to identify effective strategies for post-transplant care.
Why it matters
Potential benefit: If successful, this approach could lead to improved immune recovery and overall health outcomes for transplant patients.
How similar studies have gone: While the specific approach may be novel, similar studies focusing on immune monitoring post-transplant have shown promising results.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\) Patients must be ≥ 16 years of age; * 2\) Patients receiving haploidentical allo-HSCT; * 3\) Patients have to sign an informed consent form before the start of the research procedure. Exclusion Criteria: * 1\) Tandem transplantation or multiple transplantations; * 2\) Mental or other medical conditions that make the patients unable to comply with the research treatment and monitoring requirements; * 3\) Patients who are ineligible for the study due to other factors, or will bear great risk if participating in the study.
Where it's running
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China Recruiting
Study contacts
- Study coordinator: Yahui Feng, MS
- Email: fengyahui@ihcams.ac.cn
- Phone: 022-23909051
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Linking autonomic nervous system function to acute graft-versus-host disease
This study tests whether monitoring autonomic nervous system (ANS) function can help detect acute graft-versus-host disease early in patients receiving HLA-haploidentical transplants.
-
CMV-specific immunoglobulin to prevent CMV problems in children getting allogeneic stem cell transplants
Doctors will try giving CMV-specific immunoglobulin to children having allogeneic stem cell transplants to prevent CMV reactivation and related transplant complications.
-
Assessing diabetes risk in cirrhosis patients before and after liver transplant
This study is trying to find out what factors might lead to diabetes in adults with liver cirrhosis before and after they get a liver transplant.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.